Adma Biologics Inc [ADMA] stock is trading at $14.55, up 0.07%. An important factor to consider is whether the stock is rising or falling in short-term value. The ADMA shares have gain 3.41% over the last week, with a monthly amount drifted -9.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Mizuho started tracking the stock with Buy rating on October 13, 2022, and set its price target to $5. On November 11, 2021, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $5 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $4.50 on November 09, 2021. Jefferies initiated its recommendation with a Buy and recommended $8 as its price target on June 04, 2019. H.C. Wainwright reiterated a Buy rating for this stock on April 15, 2019, and upped its price target to $13.
Adma Biologics Inc [ADMA] stock has fluctuated between $13.50 and $25.67 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Adma Biologics Inc [NASDAQ: ADMA] shares were valued at $14.55 at the most recent close of the market. An investor can expect a potential return of 9.97% based on the average ADMA price forecast.
Analyzing the ADMA fundamentals
Adma Biologics Inc [NASDAQ:ADMA] reported sales of 474.17M for the trailing twelve months, which represents a growth of 13.80%. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at 0.33%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.44%. To continue investigating profitability, this company’s Return on Assets is posted at 0.37, Equity is 0.62 and Total Capital is 0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Adma Biologics Inc’s Current Ratio is 5.33. On the other hand, the Quick Ratio is 2.78, and the Cash Ratio is 1.2. Considering the valuation of this stock, the price to sales ratio is 7.32, the price to book ratio is 8.74 and price to earnings (TTM) ratio is 17.13.
Transactions by insiders
Recent insider trading involved Grossman Adam S, President and CEO, that happened on Sep 15 ’25 when 21000.0 shares were sold. President and CEO, Grossman Adam S completed a deal on Aug 15 ’25 to sell 21000.0 shares. Meanwhile, President and CEO Grossman Adam S sold 21000.0 shares on Jul 15 ’25.
